Status, Challenges, And Prospects Of PD-1/PD-L1 Antibodies Therapeutic of Triple-Negative Breast Cancer
DOI:
https://doi.org/10.54097/kgxd0a33Keywords:
TNBC, immune checkpoint inhibitor, ICI-chemotherapy combination.Abstract
Breast cancer is a malignant tumor which has the highest incidence in the world, serious threatening to women's health. Surgery and chemotherapy are the general symmetric therapy for breast cancer. However, the worse prognosis is in triple-negative breast cancer (TNBC) compared with other types of breast cancer due to lack of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). The characteristics of low differentiation and high heterogeneity cause the tumor cells to metastasize more easily, resulting in less effect on traditional drug treatment. For now, immune checkpoint inhibitors (ICIs) show greater effect on treating some kinds of cancers by restoring T cells function. But the clinical results in TNBC are still not very satisfactory, some researchers suggest the combination treatment of ICIs with drug or target therapy can provide better effects. This review summarizes the results in clinical trials in both ICI and ICI-chemotherapy combination, describes the possibility explanations, and discuss the challenges and prospects of ICIs in the treatment of TNBC.
Downloads
References
Zarean Shahraki, Saba et al. “Time-related survival prediction in molecular subtypes of breast cancer using time-to-event deep-learning-based models.” Frontiers in oncologyvol. 13 1147604. 5 Jun. 2023, doi:10.3389/fonc.2023.1147604
Jian Zheng. "Expression of PD-L1 in triple-negative breast cancer microenvironment and its regulatory mechanism by thymosin α1 (Ridaxin) ".2022. doi:10.27652/d.cnki.gzyku.2021.000326
Ba, Hongping et al. “Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.” Journal for immunetherapy of cancer vol. 11,1 (2023): e003837. doi:10.1136/jitc-2021-003837
Loi, Sherene et al. “Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.” JCO precision oncology vol. 7 (2023): e2200317. doi:10.1200/PO.22.00317
Samanta D, Park Y, Ni X, et al. Chemotherapy induces enrichment of CD47+/CD73+/PDL1+immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci U S A. 2018;115(6):E1239-E1248. doi:10.1073/pnas.1718197115
Zidi O, Souai N, Raies H, et al. Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers. Molecules. 2021;26(8):2266. Published 2021 Apr 14. doi:10.3390/molecules26082266
Cao B, Li M, Zha W, et al. Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells. Metabolomics. 2013;9(5):960-973. doi:10.1007/s11306-013-0517-x
Mukhtar, Rita A et al. “Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.” Annals of surgery vol. 278,3 (2023): 320-327. doi:10.1097/SLA.0000000000005968
Fu, Xiaoyu et al. “Mechanism of PARP inhibitor resistance and potential overcoming strategies.” Genes & diseases vol. 11,1 306-320. 24 Mar. 2023, doi:10.1016/j.gendis.2023.02.014
Zhang, Zhizhu et al. “Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.” International journal of molecular sciences vol. 23,13 7353. 1 Jul. 2022, doi:10.3390/ijms23137353
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
